Phase II meningococcal B vesicle vaccine trial in New Zealand infants

Archives of Disease in Childhood

Volumn 94, Issue 10, 2009, Pages 745-751

  Jackson, C ^a   Lennon, Diana R ^a   Sotutu, V T K ^a   Yan, J ^a   Stewart, J M ^a   Reid, S ^b   Crengle, S ^a   Oster, P ^c   Ypma, E ^c   Aaberge, I ^d   Mulholland, K ^e   Martin, D R ^f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Ropata Medical Centre   (New Zealand)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; FEBRILE CONVULSION; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; IRRITABILITY; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; URTICARIA; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SINGLE-BLIND METHOD;

EID: 70349406755     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.132571     Document Type: Article

References (39)

1. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004;23:S274-79.
2. Public Health Agency of Canada. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 2007;33:1-15.
3. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningoccal disease in Europe. FEMS Microbiol Rev 2007;31:27-36. (Pubitemid 46058817)
4. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207; discussion 208-210
5. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-1096
6. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-829
7. Martin DR, Walker SJ, Baker MG, et al. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998;177:497-500.
8. Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972;126:514-521
9. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-357
10. Frasch CE, Chapman SS. Classification of Neisseria meningitidis group B into distinct serotypes. 3. Application of a new bactericidal-inhibition technique to distribution of serotypes among cases and carriers. J Infect Dis 1973;127:149-154
11. Griffiss JM, Brandt BL, Broud DD, et al. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis 1984;150:71-79
12. Jones DM, Eldridge J. Development of antibodies to meningococcal protein and lipopolysaccharide serotype antigens in healthy-carriers. J Med Microbiol 1979;12:107-111 (Pubitemid 9174820)
13. van der Voort ER, van der Ley P, van der Biezen J, et al. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 1996;64:2745-2751
14. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520-1527 (Pubitemid 29200936)
15. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol 1995;24:1050-1057
16. De Moraes JC, Camargo MC, Barbosa H, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-1078
17. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994;62:4419-4424 (Pubitemid 2144134)
18. Thornton V, Lennon D, Rasanathan K, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006;24:1395-1400 (Pubitemid 43222049)
19. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007;26:345-350 (Pubitemid 46596661)
20. Hosking J, Rasanathan K, Chan Mow F, et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific group B meningococcal vaccine given to 8-12 year old children. Clin Vaccine Immunol 2007;14:1393-1399 (Pubitemid 350304030)
21. Wong S, Lennon D, Jackson C, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009;28:385-390
22. Perkins BA, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998;177:683-691 (Pubitemid 28099883)
23. Djupesland P, Bjune G, Hoiby E, et al. Serogroup B meningococcal disease in the Norwegian armed forces. Eur J Public Health 1997;7:261-266
24. Zhang Q, Pettitt E, Burkinshaw R, et al. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J 2002;21:209-213 (Pubitemid 34214138)
25. Ministry of Health. Immunisation handbook 2002. Wellington: New Zealand Ministry of Health, 2002.
26. Martin D, McCallum L, Glennie A, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 2005;23:2218-2221 (Pubitemid 40341455)
27. Agresti A, Coull B. Approximation is better than 'exact' for interval estimation of binomial proportions. Am Stat 1998;52:119-126
28. Jackson C, Lennon D, Wong S, et al. Persistence of immune response in New Zealand adults and children after 3 doses of MeNZB and response to a 4th dose in toddlers. Poster G-1698/324 presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007.
29. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-1326
30. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969;129:1327-1348
31. Martin D, Lopez L, McDowell R. The epidemiology of meningococcal disease in New Zealand in 2005. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR). Wellington, NZ: Ministry of Health, 2006.
32. Peeters CC, Rumke HC, Sundermann LC, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:1009-1015
33. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-737 (Pubitemid 36091989)
34. Borrow R, Aaberge IS, Santos GF, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005;12:970-976
35. Ameratunga SN, Macmillan A, Stewart J, et al. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy. Vaccine 2005;23:2231-2234 (Pubitemid 40341458)
36. Kelly C, Arnold R, Galloway Y, et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817-823 (Pubitemid 47428901)
37. Lennon D, Stewart J, Crengle S. Re: "A prospective study of the effectiveness of the New Zealand meningococcal B vaccine". Am J Epidemiol 2008;167:1140-1141 (Pubitemid 351601248)
38. Lopez L, Martin D. Meningococcal disease report: December 2007. Prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited. Wellington, NZ: Ministry of Health, 2007.
39. Wenger JD. Serogroup B meningococcal disease: new outbreaks, new strategies. JAMA 1999;281:1541-1543 (Pubitemid 29200940)